Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Oramed PharmaceuticalsGalera TherapeuticsLarimar TherapeuticsGalectoTyme Technologies
SymbolNASDAQ:ORMPNASDAQ:GRTXNASDAQ:LRMRNASDAQ:GLTONASDAQ:TYME
Price Information
Current Price$8.34$6.64$10.30$5.70$1.33
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.31.61.61.61.3
Analysis Score3.53.53.53.53.5
Community Score3.12.12.14.12.4
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.70.00.0
Earnings & Valuation Score0.00.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$16.75$17.00$29.00$14.00$9.50
% Upside from Price Target100.84% upside156.02% upside181.55% upside145.61% upside614.29% upside
Trade Information
Market Cap$252.10 million$176.33 million$151.99 million$146.01 million$185.21 million
Beta1.981.890.65N/A0.94
Average Volume771,48670,54771,65833,9019,802,050
Sales & Book Value
Annual Revenue$2.71 millionN/AN/AN/AN/A
Price / Sales93.03N/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.40 per share$2.81 per share$17.22 per shareN/A$0.15 per share
Price / Book5.96N/AN/AN/AN/A
Profitability
Net Income$-11,510,000.00$-51,930,000.00$-45,410,000.00N/A$-22,000,000.00
EPS($0.56)($16.31)N/AN/A($0.17)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-424.76%N/AN/AN/AN/A
Return on Equity (ROE)-45.93%-151.01%-38.70%N/A-192.69%
Return on Assets (ROA)-30.33%-60.72%-31.40%N/A-111.68%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio8.93%8.79%20.82%N/A3.62%
Quick Ratio8.93%8.79%20.82%N/A3.62%
Ownership Information
Institutional Ownership Percentage6.03%75.41%88.76%N/A13.01%
Insider Ownership Percentage16.10%19.30%5.10%N/A25.51%
Miscellaneous
EmployeesN/A32282318
Shares Outstanding30.23 million24.98 million15.37 million25.26 million130.43 million
Next Earnings Date7/6/2021 (Estimated)5/11/2021 (Estimated)5/6/2021 (Estimated)7/5/2021 (Estimated)5/19/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Will Tyme Technologies, Inc. (NASDAQ:TYME) in 2021 Be Worth Your Money?Will Tyme Technologies, Inc. (NASDAQ:TYME) in 2021 Be Worth Your Money?
marketingsentinel.com - April 20 at 12:40 PM
Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Michael Demurjian Sells 20,000 SharesTyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Michael Demurjian Sells 20,000 Shares
americanbankingnews.com - April 20 at 10:58 AM
If You’re Not Bullish on Tyme Technologies, Inc. (NASDAQ:TYME) Now, You’ll Kick Yourself LaterIf You’re Not Bullish on Tyme Technologies, Inc. (NASDAQ:TYME) Now, You’ll Kick Yourself Later
stocksregister.com - April 19 at 11:37 AM
Claremorris-based company sees increase in demand for self-service checkoutsClaremorris-based company sees increase in demand for self-service checkouts
midwestradio.ie - April 18 at 5:38 PM
 Brokerages Anticipate Tyme Technologies, Inc. (NASDAQ:TYME) to Post -$0.06 Earnings Per Share Brokerages Anticipate Tyme Technologies, Inc. (NASDAQ:TYME) to Post -$0.06 Earnings Per Share
americanbankingnews.com - April 17 at 8:13 PM
Steve Hoffman Sells 41,750 Shares of Tyme Technologies, Inc. (NASDAQ:TYME) StockSteve Hoffman Sells 41,750 Shares of Tyme Technologies, Inc. (NASDAQ:TYME) Stock
americanbankingnews.com - April 15 at 4:54 PM
Vertical farms using cloud networks to control and analyze lightingVertical farms using cloud networks to control and analyze lighting
ledsmagazine.com - April 14 at 9:05 AM
Michael Demurjian Sells 20,000 Shares of Tyme Technologies, Inc. (NASDAQ:TYME) StockMichael Demurjian Sells 20,000 Shares of Tyme Technologies, Inc. (NASDAQ:TYME) Stock
americanbankingnews.com - April 13 at 8:16 PM
Tyme Technologies, Inc. (NASDAQ:TYME)’s Share Price Fell Recently, Although No Trouble Is On The HorizonTyme Technologies, Inc. (NASDAQ:TYME)’s Share Price Fell Recently, Although No Trouble Is On The Horizon
stocksregister.com - April 12 at 9:33 AM
Is hyperlocal product sourcing a real opportunity for grocers?Is hyperlocal product sourcing a real opportunity for grocers?
supermarketnews.com - April 5 at 5:16 PM
Tyme hires acting CMO 4 months after new CEO takes the wheelTyme hires acting CMO 4 months after new CEO takes the wheel
fiercebiotech.com - April 1 at 12:29 PM
Long Island growers see vertical farms as the future of agricultureLong Island growers see vertical farms as the 'future of agriculture'
newsday.com - April 1 at 7:24 AM
It’s Always Sunny at St. Petersburg’s Brick Street FarmsIt’s Always Sunny at St. Petersburg’s Brick Street Farms
wusfnews.wusf.usf.edu - March 31 at 2:29 PM
 Analysts Expect Tyme Technologies, Inc. (NASDAQ:TYME) Will Announce Earnings of -$0.06 Per Share Analysts Expect Tyme Technologies, Inc. (NASDAQ:TYME) Will Announce Earnings of -$0.06 Per Share
americanbankingnews.com - March 31 at 2:16 AM
Moderna Covid vaccine to be introduced in UK from AprilModerna Covid vaccine to be introduced in UK from April
telegraph.co.uk - March 30 at 6:26 PM
Facebook temporarily freezes Venezuelan president Nicolás Maduro’s pageFacebook temporarily freezes Venezuelan president Nicolás Maduro’s page
medianama.com - March 30 at 8:23 AM
Who’s expanding in the indoor produce worldWho’s expanding in the indoor produce world
greenhousemag.com - March 30 at 3:23 AM
Tyme Technologies, Inc. (NASDAQ:TYME) Insider Sells $74,732.50 in StockTyme Technologies, Inc. (NASDAQ:TYME) Insider Sells $74,732.50 in Stock
americanbankingnews.com - March 29 at 4:50 PM
Insider Selling: Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Sells 20,000 Shares of StockInsider Selling: Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Sells 20,000 Shares of Stock
americanbankingnews.com - March 29 at 4:50 PM
Venezuelan presidents Facebook page flagged for COVID-19 misinformationVenezuelan president's Facebook page flagged for COVID-19 misinformation
msn.com - March 29 at 7:20 AM
Facebook Freezes Venezuelan President’s Page Over COVID MisinformationFacebook Freezes Venezuelan President’s Page Over COVID Misinformation
voanews.com - March 28 at 8:53 AM
Facebook freezes Venezuelan President Maduro’s page over COVID claimFacebook freezes Venezuelan President Maduro’s page over COVID claim
adaderana.lk - March 27 at 5:52 PM
Venezuelan presidents Facebook page flagged for COVID-19 misinformation: ReutersVenezuelan president's Facebook page flagged for COVID-19 misinformation: Reuters
thehill.com - March 27 at 5:52 PM
Facebook freezes Venezuela President Maduro’s page over COVID misinformationFacebook freezes Venezuela President Maduro’s page over COVID misinformation
adaderana.lk - March 27 at 5:52 PM
Facebook freezes Venezuela president Maduros page over COVID-19 misinformationFacebook freezes Venezuela president Maduro's page over COVID-19 misinformation
dunyanews.tv - March 27 at 12:44 PM
DateCompanyBrokerageAction
4/20/2021Oramed PharmaceuticalsCanaccord GenuityInitiated Coverage
2/15/2021Oramed PharmaceuticalsAegisReiterated Rating
2/9/2021Oramed PharmaceuticalsNational SecuritiesInitiated Coverage
12/3/2020Oramed PharmaceuticalsAlliance Global PartnersInitiated Coverage
7/13/2020Oramed PharmaceuticalsHC WainwrightReiterated Rating
9/11/2019Oramed PharmaceuticalsLADENBURG THALM/SH SHInitiated Coverage
7/16/2018Oramed PharmaceuticalsB. RileyDowngrade
12/16/2020Galera TherapeuticsCredit Suisse GroupUpgrade
10/28/2020Galera TherapeuticsSmith Barney CitigroupBoost Price Target
12/2/2019Galera TherapeuticsBTIG ResearchInitiated Coverage
12/2/2019Galera TherapeuticsCitigroupInitiated Coverage
12/2/2019Galera TherapeuticsBank of AmericaInitiated Coverage
2/10/2021Larimar TherapeuticsJMP SecuritiesInitiated Coverage
2/1/2021Larimar TherapeuticsWilliam BlairInitiated Coverage
3/22/2021GalectoSVB LeerinkLower Price Target
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.